← Leaderboards
Rebecca Ashare
State University Of New York At Buffalo
$9,515,606
Attributed
$16,256,298
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,256,298 · 9
By mechanism
R01$13,078,023 · 5
U01$1,905,214 · 1
K23$745,548 · 1
R21$437,600 · 1
F31$89,913 · 1
Top collaborators
- Salimah H. Meghani10 shared
- Brooke Worster6 shared
- Ronald G Collman5 shared
- Robert Gross4 shared
- Roger Vilardaga3 shared
- Shannon Madore Nugent2 shared
- Francis Joseph Mcclernon1 shared
- Shannon Nugent1 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Larry W Hawk$8,784,565
- Pinaki Sarder$7,231,909
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsSmokingSamplingSmokerQuality Of LifeSmoking CessationResearch DesignReportingMalignant NeoplasmsTobacco UseSeveritiesResponsePrimary OutcomeSleepAbstinenceNicotineMedicalAreaCognitive DeficitsCognitiveHiv InfectionsNicotine DependenceSmoking BehaviorSchedule
Grant awards (37)
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$662,839
R01 · FY2025 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$629,354
U01 · FY2025 · CA · contact PI
Hybrid Trial of a Tailored Smoking Cessation Digital Therapeutic for Persons Living with HIV$619,707
R01 · FY2025 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$70,531
R01 · FY2025 · CA
Hybrid Trial of a Tailored Smoking Cessation Digital Therapeutic for Persons Living with HIV$675,089
R01 · FY2024 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$620,322
R01 · FY2024 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$599,442
U01 · FY2024 · CA · contact PI
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$68,605
R01 · FY2024 · CA
Hybrid Trial of a Tailored Smoking Cessation Digital Therapeutic for Persons Living with HIV$1
R01 · FY2024 · CA
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$676,418
U01 · FY2023 · CA · contact PI
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$642,629
R01 · FY2023 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$51,212
R01 · FY2023 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$699,429
R01 · FY2022 · CA
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$432,874
R01 · FY2022 · HL
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$418,876
R01 · FY2022 · HL
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction$733,510
R01 · FY2021 · DA · contact PI
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$536,730
R01 · FY2021 · HL
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction$741,975
R01 · FY2020 · DA · contact PI
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers$642,213
R01 · FY2020 · DA · contact PI
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$541,423
R01 · FY2020 · HL
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction$759,622
R01 · FY2019 · DA · contact PI
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers$660,298
R01 · FY2019 · DA · contact PI
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction$759,622
R01 · FY2018 · DA · contact PI
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers$660,298
R01 · FY2018 · DA · contact PI
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction$759,622
R01 · FY2017 · DA · contact PI
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers$660,298
R01 · FY2017 · DA · contact PI
Repurposing cholinesterase inhibitors for smoking cessation$119,596
K23 · FY2017 · DA · contact PI
Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers$660,298
R01 · FY2016 · DA · contact PI
Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation$237,600
R21 · FY2016 · DA · contact PI
Repurposing cholinesterase inhibitors for smoking cessation$156,488
K23 · FY2016 · DA · contact PI
Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation$200,000
R21 · FY2015 · DA · contact PI
Repurposing cholinesterase inhibitors for smoking cessation$156,488
K23 · FY2015 · DA · contact PI
Repurposing cholinesterase inhibitors for smoking cessation$156,488
K23 · FY2014 · DA · contact PI
Repurposing cholinesterase inhibitors for smoking cessation$156,488
K23 · FY2013 · DA · contact PI
Smoking Abstinence and Impulsive Behavior: A Multi-Process Model$30,107
F31 · FY2009 · DA · contact PI
Smoking Abstinence and Impulsive Behavior: A Multi-Process Model$29,903
F31 · FY2008 · DA · contact PI
Smoking Abstinence and Impulsive Behavior: A Multi-Process Model$29,903
F31 · FY2007 · DA · contact PI